1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.

This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. That said, here is one industry titan that still has big upside potential and two that could be stalling.

Two Mega-Cap Stocks to Sell:

JPMorgan Chase (JPM)

Market Cap: $828.3 billion

Tracing its roots back to 1799 when its earliest predecessor was founded by Aaron Burr, JPMorgan Chase (NYSE:JPM) is a leading financial services company offering investment banking, consumer banking, commercial banking, and asset management services globally.

Why Are We Hesitant About JPM?

1. The company has faced growth challenges as its 6.9% annual revenue increases over the last two years fell short of other banking companies
2. Inferior net interest margin of 2.6% means it must compensate for lower profitability through increased loan originations
3. Overall productivity is expected to decrease over the next year as Wall Street thinks its efficiency ratio will degrade by 2.8 percentage points

JPMorgan Chase is trading at $307.19 per share, or 2.2x forward P/B. Check out our free in-depth research report to learn more about why JPM doesn’t pass our bar.

Oracle (ORCL)

Market Cap: $442.5 billion

Starting as a database company in 1977 and now powering mission-critical systems across the globe, Oracle (NYSE:ORCL) provides enterprise software and hardware products and services that help businesses manage their information technology needs.

Why Do We Avoid ORCL?

1. Offerings struggled to generate meaningful interest as its average billings growth of 10.4% over the last year did not impress
2. Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 10.8 percentage points
3. Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders

At $153.40 per share, Oracle trades at 6.2x forward price-to-sales. To fully understand why you should be careful with ORCL, check out our full research report (it’s free).

One Mega-Cap Stock to Watch:

AbbVie (ABBV)

Market Cap: $411.6 billion

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Why Could ABBV Be a Winner?

1. Unparalleled scale of $61.16 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
2. Robust free cash flow margin of 38% gives it many options for capital deployment
3. Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures

AbbVie’s stock price of $232.50 implies a valuation ratio of 15.9x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.